Credit: Siemens Healthineers

On June 9, 2022, Siemens Healthineers China officially released the company's new "National Intelligence Innovation" localization strategy, announcing that it will deeply participate in Healthy China construction as a "Chinese company" through three demensions of "promoting the localization of the entire product line", "further in-depth innovation and research and development based on Chinese market demand", and "promoting the upgrading of local business models".

At the same time, it was announced that the high-profile Siemens Healthineers Shanghai laboratory diagnostics factory is expected to be completed in Pudong by the end of 2022. At that time, it will become the first in vitro diagnostic reagent production base of Siemens Healthineers in the Asia-Pacific region, and its R&D center project is also actively advancing.

Tao Lin, Member of the Board of Directors of Siemens Healthineers and President of Siemens Healthineers Asia Pacific, said: "China has always been of great strategic significance to Siemens Healthineers. It contains huge potential and has its own unique market environment. Siemens Healthineers deeply integrates global strategy and local development concept, and regards "Healthy China" as one of the important opportunities and action priorities in the new stage of the company's global "2025 strategy". We also believe that the localization strategy of 'National Intelligence Innovation' that emerges as the times require is the best solution for us to promote the construction of a healthy China. "

As one of the first medical technology companies to enter China, Siemens Healthineers closely follows the development of China medical and health industry, and steadily promotes the upgrading of its localization strategy with the determination of “In China, For China”. "For 30 years, Siemens Healthineers has witnessed and participated in the rapid development of China economy and national living standard. We are committed to solving the most urgent medical needs of Chinese society and become a trusted partner of China medical system and patients. A new localization strategy The proposal of the new localization strategy is also a major measure for Siemens Healthineers to further integrate into China new development. " said Wang Hao, President of Siemens Healthineers Greater China.

According to Wang Hao, the Shanghai Laboratory Diagnostic Factory, which will be completed by the end of the year, will mainly produce immunological reagents. "The R&D center of the Shanghai Laboratory Diagnostic Factory is also being actively promoted. Through independent research and development, the factory will work with local partners to launch unique laboratory diagnostic products that meet the needs of the Chinese market. "